Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
about
Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancerCan knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Oral antineoplastic agents: how do we care about adherence?The role of observational studies in optimizing the clinical management of chronic myeloid leukemiaMulticenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With ImatinibHow could patient reported outcomes improve patient management in chronic myeloid leukemia?Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Adherence with capecitabine: A population-based analysis based on prescription refill data.First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study.Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitorsMeasuring symptoms as a critical component of drug development and evaluation in hematological diseasesChronic Myeloid Leukemia in India.Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.The use of erlotinib in daily practice: a study on adherence and patients' experiences.Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).Early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients.A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Oral anticancer agent medication adherence by outpatientsCritical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerationsImatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysisPerspectives on adherence and persistence with oral medications for cancer treatment.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaThe change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.Predicting blood pressure outcomes using single-item physician-administered measures: a retrospective pooled analysis of observational studies in BelgiumCritical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study.Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia.Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.How we will treat chronic myeloid leukemia in 2016.Patients' self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis.A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival.
P2860
Q24632347-112FD546-F2AA-4CF6-B7A7-991C2A0B3911Q26859144-47DCFEC5-750B-4B6F-8C52-C63BAEF7F892Q28082909-1C992406-3DB0-4A74-8E98-531187D412A1Q28085149-02042530-F5E9-40EF-95E0-24548DDDB02AQ29999611-DE3D9EB5-C333-42D5-AEC3-E809A5FE3C40Q30241092-FD22C038-D53C-47DF-8F97-8822F133BF6BQ30242015-10BA100B-D2E7-4CF0-90DC-F84FBDFCC779Q31140272-AC694D4B-3D7C-4A73-967B-9D04AA8E7095Q33392977-D89A8BD2-87A6-4CDE-9A06-64FAD1403DCFQ33394772-C3EF1487-0FE4-4284-A51C-C84556E10EA0Q33397085-F78850B1-B6A0-419C-B892-36C55EF6EC03Q33420661-01229A52-1709-4F75-B3FB-F514E7A221EAQ33603379-AB809665-81E1-49F0-8FEA-0B111C30A590Q33705743-0ACC1E34-AFE8-4755-B361-E69A5E143D00Q33859551-B0F4D703-1DFB-4DED-A177-4D15AE8D4362Q33885999-D1B36D66-AFE4-4DA6-8045-826FB19E91DAQ33903030-5BE99568-40BF-4D40-9A43-F36C5A616B34Q33921067-6776456A-C5A6-4519-B32C-00110CC8026BQ33948681-9EE63FA2-BE49-43C8-9099-FD83FC514FFEQ34055591-E3A919E5-C2AF-4E0C-BB84-5F4B85C34892Q34174599-7E1C0025-144F-4E87-AC5E-344F11F3310FQ34194110-D9063378-1B24-44B7-AA7D-3C8A72DE6C96Q34272962-52381F9E-C532-41C6-B652-429506BB91EDQ34293339-4C412214-B075-42EB-83C6-84441AAE4635Q34418437-C583C684-BE8D-4E57-9924-B08311ED7E71Q34433289-B471662A-BD36-406B-B33E-6227F54004BBQ34445704-A72AEE92-E107-44F3-81B3-A42823F10DAFQ34459748-6608CB44-C5EE-4472-9F7C-574F101AEF65Q34522789-E9933C09-E9B2-459F-95D2-F0DD853727E2Q34736154-CAD7F631-09BD-4F76-BCEF-B2DDA9C00F19Q34750582-789F6934-D26B-4276-986E-A40CDB902AD7Q34769144-E0B66DE7-1027-4290-8C9E-CBA7016530F0Q34894883-7EDCA0B9-5357-423D-92BF-7BDFAB97008AQ35117747-1186E261-0809-47A9-B14B-EE33140FF849Q35130028-780EBFC7-D33D-4F3D-8478-434C1BE0EB1DQ35142510-D6C38C88-F238-4A1E-B9F2-26B7B18168E1Q35168777-DE9DD9DC-DA54-4C8F-92F7-68D14A78F37BQ35269378-7874DD33-54F4-4B7C-BE06-2CC7FB89FF10Q35444531-9CCB9C0E-5330-44E6-ADBD-7C0FD7E2CA4CQ35494151-1A141DD2-5043-4F18-A6E1-2E68153000F3
P2860
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Prevalence, determinants, and ...... id leukemia: the ADAGIO study.
@en
Prevalence, determinants, and ...... id leukemia: the ADAGIO study.
@nl
type
label
Prevalence, determinants, and ...... id leukemia: the ADAGIO study.
@en
Prevalence, determinants, and ...... id leukemia: the ADAGIO study.
@nl
prefLabel
Prevalence, determinants, and ...... id leukemia: the ADAGIO study.
@en
Prevalence, determinants, and ...... id leukemia: the ADAGIO study.
@nl
P2093
P50
P921
P1433
P1476
Prevalence, determinants, and ...... oid leukemia: the ADAGIO study
@en
P2093
Gregor Verhoef
Ivo Abraham
Karen MacDonald
Koen Van Eygen
Lucien Noens
Marie-Anne van Lierde
Philippe Martiat
Philippe Mineur
Robrecht De Bock
P304
P356
10.1182/BLOOD-2008-12-196543
P407
P577
2009-04-06T00:00:00Z